Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TP-II: Neoadjuvant Trastuzumab/Pertuzumab with Chemo vs Endocrine in HER2+/HR+ Breast Cancer
NCT03272477Phase 2Completed
- Sponsor
- Palleos Healthcare
- Start
- Oct 2017
- Primary completion
- Jul 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pertuzumab and trastuzumab in breast cancer (2 arms), sponsored by Palleos Healthcare. Primary endpoint: Pathological Complete Response at 14 weeks. Started Oct 2017; status: completed.
02
Drugs
pertuzumabtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03272477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03272477.